MEI Pharma, Inc.

307 articles with MEI Pharma, Inc.

• MEI Pharma Announces Pricing of Public Offering of Common Stock - Dec 02, 2021

  12/2/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds of $45,500,000.

• MEI Pharma Announces Proposed Public Offering of Common Stock - Nov 30, 2021

  11/30/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it plans to offer 17,500,000 shares of its common stock in an underwritten public offering.

• MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

  11/30/2021

  MEI Pharma, Inc. today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma.

• MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma

  11/29/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating zandelisib in patients with relapsed or refractory follicular lymphoma.

• MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors

  11/23/2021

  MEI Pharma, Inc. today announced the appointment of Mr. Sujay Kango to its board of directors effective November 22, 2021.

• MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights

  11/10/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2021 and highlighted recent corporate progress.

• MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma

  11/10/2021

  MEI Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib for the treatment of follicular lymphoma.

• MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting

  11/4/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that three abstracts highlighting data and information from three oncology drug candidates in its pipeline will be presented at the upcoming 63rd Annual American Society of Hematology Annual Meeting to be held December 11 – 14, 2021.

• MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021

  11/1/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 133,000 shares of the company’s common stock to two new employees.

• MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 136,000 shares of the company’s common stock to three new employees.

• MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/22/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a company overview and business update at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:00 p.m. Eastern Time.

• MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2021

  9/3/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 132,000 shares of the company's common stock to four new employees.

• MEI Pharma to Present at Two Healthcare Conferences in September 2021

  9/2/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it will present a company overview and business update at two upcoming investor conferences.

• MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights

  9/2/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for its fiscal year ended June 30, 2021.

• MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021

  8/26/2021

  MEI Pharma, Inc. today announced that the Company will release its 2021 fiscal year end financial results after the close of the U.S. financial markets on September 2, 2021.

• MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma

  8/17/2021

   MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient in a Phase 3 study of zandelisib known as COASTAL.

• MEI Pharma Announces Planned Chief Financial Officer Transition

  8/5/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that Brian Drazba, chief financial officer of MEI Pharma, has informed the company that he is retiring.

• MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021

  8/2/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 306,000 shares of the company's common stock to seven new employees.

• MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer

  7/7/2021

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Tina C. Beamon, J.D., as chief compliance officer, effective immediately

• MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021 - July 01, 2021

  7/1/2021

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 169,000 shares of the company's common stock to three new employees.